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Background: In Tunisia, diabetes mellitus and hemoglobinopathies are major public health problems. Glycated
hemoglobin (HbA1c) is recommended for long-term monitoring of diabetes mellitus, but the presence of
hemoglobin variants may interfere with HbA1c measurement. The aim was to determine the prevalence
of hemoglobin variants in Tunisian diabetics and optimize the monitoring of diabetics using HbA1c.
Methods: The study enrolled 9,792 Tunisian diabetic patients. HbA1c was measured by cation-exchange high-
pressure liquid chromatography (HPLC). All the chromatograms were analyzed for the presence of Hb variants.
Results: We identified 228 cases (2.33%) of Hb variants with D-10 HPLC (Bio-Rad): 191 with HbA/S trait, 27
with HbA/C trait, and 10 hemoglobin variants with the mention ‘Variant-Window’ on the chromatograms
and subsequently identified as HbA/S on Variant I HPLC (Bio-Rad). Thus, the prevalence of HbS was 2.05%.
We did not find any homozygous variant. All HbA1c results were reported to the treating physician.
Conclusions: To evaluate glycated hemoglobin in populations with a high prevalence of hemoglobinopathies,
we should use the HPLC method, which is easy, economical, and reliable. Based on an algorithm, hemo-
globin variants visualized on HPLC should be reported to the physician to improve the management of
patients.
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T
he prevalence of diabetes mellitus (DM) is in-
creasing rapidly worldwide. The World Health
Organization estimated that more than 366 million
people will suffer from DM by the year 2030 (1). For ex-
ample, in 2011 about 14 million individuals were estimated
to have diabetes in Africa, and this is expected to rise to 28
million by 2030 (2). In Tunisia, the overall diabetes preva-
lence increased significantly during the last 15 years. This
rate has more than doubled, reaching 9.90% in recent years
(3). This increasing trend of DM prevalence emphasizes
the need to rely on glycated hemoglobin (HbA1c) for
managing glycemic control and long-term monitoring.
HbA1c has been shown to be directly related to the risk of
developing diabetes complications. Treatment goals for
HbA1c have been established, and this biomarker was
recently recommended by the American Diabetes Asso-
ciation for DM diagnosis (4). Therefore, accurate and
precise measurement of HbA1c is extremely important (5).
Several studies indicated that there are differences in
HbA1c among racial groups (6). Herman et al. showed
that HbA1c levels are different among racial and ethnic
groups, and a particular threshold HbA1c value may
not be appropriate for all ethnic groups because of the
presence of hemoglobin variants (7).
Hemoglobinopathies are associated with decreased
erythrocyte survival and decreased glycohemoglobin per-
centages. Hemoglobinopathies are frequent in many parts
of the world: more than 900 hemoglobin variants have
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been described, and at least 43.20% of all possible single-
point mutations have been identified (8). These inherited
hemoglobin disorders are spread all around the world
because of migration, and their high frequency and clinical
severity in Africa make them a major public health
problem (9). The World Health Organization noted that
more than 70% of all hemoglobin disorders are localized
in Africa (10). Fattoum (11) reported that systematic
surveys done in Tunisia show a prevalence of hemoglobi-
nopathy carriers in Tunisia of 4.48%, reaching 12.5%
in some regions. Many hemoglobin variants have mini-
mal clinical significance and are sometimes a fortuitous
finding when HbA1c is analyzed (12). However, their
presence may cause a spurious increase or decrease in
the HbA1c result, depending on the methodology and
the properties of the hemoglobin (13, 14). Hemoglobin
S (HbS) is the most common variant worldwide and is
consequently found in a significant proportion of dia-
betic patients who are tested for HbA1c. Several studies
investigated the prevalence of DM or of hemoglobinopa-
thies in the Tunisian general population, but there is no
study on the prevalence of hemoglobinopathies among
the Tunisian diabetic population. The aim of this study
was to determine the prevalence of hemoglobin variants in
Tunisian diabetic patients and to optimize the monitoring
of diabetics using HbA1c.
Methods
Our study enrolled all 9,792 Tunisian diabetic patients
consulting at or staying in Charles Nicolle Hospital, Tunis,
Tunisia between January 2009 and December 2009. For all
these patients, HbA1c was used as an index of mean
glycemia over the preceding 23 months. Patients who
show up repeatedly for HbA1c in the hospital were counted
only once. Measurement of HbA1c was done by cation-
exchange high-pressure liquid chromatography (HPLC)
on a D-10 system (Bio-Rad Laboratories, Hercules, CA,
USA) using reagents according to the manufacturer’s
instructions. This method quantifies HbA1c, which is
defined as Hb A with glucose attached to the N-terminal
valine beta chain, as a percentage of HbA1c: (HbA1c area/
total HbA area of the chromatogram)*100. When HbS,
HbC, or ‘Variant-Window’ was detected in a sample on
HPLC D-10, a ‘corrected HbA1c value’ was automatically
obtained by exclusion of the area of the variant from the
total area of the chromatogram. Correction is necessary
because retention times of glycated HbS and glycated
HbC are similar to that of the major HbA fraction on the
chromatogram, so these fractions coelute with HbA (15).
When a patient’s chromatogram showed a hemoglobin
variant during the measurement of HbA1c, it was re-
ported to the ordering clinician, who then explained to
the patient that he or she has a hemoglobin variant and
requested approval to perform more tests on the blood
sample. In that case, the blood sample was analyzed
further using the b thalassemia short program on the
HPLC Variant I analyzer (Bio-Rad Laboratories) in order
to identify and quantify the variant. Whenever an HbS
variant was found on a chromatogram, the presence of
HbS was confirmed by sickle solubility testing. Hemoglo-
bin variants whose retention time was not listed by the
supplier on HPLC D-10 were called ‘unknown’, and those
mentioned on the chromatogram by ‘Variant-Window’
had a retention time registered but their identification
needed to be completed on HPLC Variant I. For both
‘unknown’ and ‘Variant-Window’, identification of the
hemoglobin variant was completed by using two methods:
b thalassemia short program on HPLC Variant I and
electrophoresis of hemoglobin at alkaline pH. In accor-
dance with guidelines for screening and diagnosis of
hemoglobinopathies, presumptive identification was based
on a minimum of two techniques based on different
principles (16).
Informed consent was obtained from all patients for
whom Hb variants were determined by additional tests.
Results
The study enrolled 9,792 patients (4,291 males and 5,501
females); the male-to-female ratio was 0.781.00. Of the
9,792 patients, 9,564 (97.70%) had no hemoglobin variant
(Fig. 1a). The chromatograms produced by the HPLC D-
10 method showed the presence of hemoglobin variants in
228 cases (2.30%). Analysis of blood samples of hemoglo-
bin variant carriers on Variant I identified 191 cases of
heterozygous hemoglobin S (Fig. 1b) (confirmed by sickle
solubility testing), 27 cases of heterozygous hemoglobin C
(Fig. 1c), and 10 cases of heterozygous hemoglobin with
a mention of ‘Variant-Window’ on the chromatogram
(Fig. 1d). There were no cases of homozygous hemoglobin
variants. For the 10 cases, the b thalassemia short program
on HPLC Variant I and electrophoresis of hemoglobin at
alkaline pH revealed that they were all heterozygous
hemoglobin S. The 10 samples were positive in sickle
solubility testing. Finally, we identified 201 cases of HbA/S
and 27 cases of HbA/C. Thus, the prevalence of the HbS
trait was 2.05%.
Discussion
The Diabetes Control and Complications Trial reference
method for measurement of HbA1c was cation-exchange
HPLC (17). Our analysis using this method showed a
prevalence of hemoglobin variants of 2.30% among all
the diabetic patients attending the hospital during the
1-year period of the study. Moreover, the prevalence of
HbS was 2.05%. This is in agreement with the prevalence
of HbS found by Fattoum in the general population in
Tunisia (1.90%) (9). Recent detailed reviews on hemoglo-
binopathies in Tunisia reported that sickle cell disease
is by far the most frequent hemoglobinopathy in North
Africa; its average frequency in Algeria was 0.803.50%
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and in Morocco 1.20% (18). Until now, there have been
no data on the prevalence of hemoglobin variants in the
diabetic populations in Africa. However, in Singapore,
Saw et al. (13) studied 5,628 chromatograms of diabetics
and noted a prevalence of 2.30% of hemoglobin variants.
As the program of measurement of HbA1c on D-10
Fig. 1. Chromatograms from samples of diabetic patients without and with hemoglobin variants (HPLC D-10). (a)
sample without hemoglobin variant; (b) sample with HbS; (c) sample with HbC; (d) sample with hemoglobin variant not
recognized.
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system does not detect a and b thalassemia, we cannot
compare our prevalence with their epidemiologic data.
The presence of hemoglobin variants among diabetics
has a consequence for diabetic survey analysis. HbA1c is
strongly correlated with complications of DM, so its meas-
urement must be accurate and precise (5). Although cation-
exchange HPLC is the reference method, the presence of
hemoglobin variants may interfere with HbA1c measure-
ments, producing falsely high or low values when the he-
moglobin variant or its glycated form cannot be separated
from hemoglobin A or HbA1c (13, 19). In contrast,
heterozygous hemoglobin S and C samples do not affect
the assay (14). Ideally, we should first detect the presence
of hemoglobin variants to decide if the HbA1c measure-
ment can be accepted at face value (monitoring of HbA1c
cannot be used if the patient is homozygous for a hemo-
globin variant or compound heterozygote). In our study,
the 228 cases of hemoglobin variants were carriers of HbS
(Hb AS) or HbC (Hb AC), so we reported the HbA1c
values. Elution time of HbS is sometimes not recognized
by the HPLC D-10, and that is why for 10 samples the
chromatogram indicates ‘Variant-Window’. However,
when an interfering hemoglobin variant is visualized or
suspected, samples should be analyzed by an alternative
method that is not affected by hemoglobin variants.
Fructosamine may be a better indicator of diabetes control
when hemoglobin variants are associated with reduced red
blood cell half-life and hence reduction of glycated
hemoglobin (13).
The presence of abnormal Hb cannot be detected by
immunoassay or the enzymatic methods used to quantify
HbA1c. Besides, these methods do not provide any
information about the proportions of the different Hb
fractions, which might be helpful in interpreting the
results (20). In managing diabetic patients, knowledge of
hemoglobinopathies affecting HbA1c determination is
essential because ignoring the presence of Hb variants
could result in mismanagement of diabetes due to false
HbA1c determinations (21).
In Tunisia, the prevalence of HbS trait in the general
population is 1.89% (9), and we propose that diabetes be
monitored by the use of a user friendly cation-exchange
HPLC, such as the D-10. When diabetic patients homo-
zygous for HbS or C or compound heterozygotes SC
are identified, they should not be monitored by HbA1c
because the life span of the red blood cells is altered (19).
The laboratory staff should add a footnote, ‘Unable to
quantitate HbA1c by this method due to the presence
of homozygous HbS or HbC variant or compound
heterozygotes SC. We suggest fructosamine or another
alternative’. This provides the physician with the infor-
mation needed to properly manage such diabetic patients.
The procedure currently used in our laboratory (Fig. 2)
explains to laboratory staff how to communicate an
Fig. 2. Procedure and interpretation of HbA1c result on cation-exchange HPLC analyzer in the presence of hemoglobin
variant.
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accurate value of HbA1c of diabetics to the physicians.
Other authors, such as Behan et al. (14), also recommend
a standardized reporting format for HbA1c that includes
notification of variant hemoglobins. In conclusion, we
show that the prevalence of variant Hb in our diabetic
population is high and that the monitoring of diabetic
patients using HbA1c should be optimized. It is also
desirable that laboratory reports on glycated hemoglobin
be standardized.
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